Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

The figure also surpassed the Zacks Consensus Estimate of $44.96. Regeneron initiated a quarterly cash dividend program and declared a dividend of $0.88 per share. The dividend is payable on March ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regeneron Pharmaceuticals ... program by a further $3 billion (now totaling $4.5 billion) and issued a modest dividend of 88 cents per share. This should help improve not only sentiment but ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to ...

Guggenheim analyst Yatin Suneja lowered the firm’s price target on Regeneron (REGN) to $940 from $950 and keeps a Buy rating on the shares. The ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $1,081 from $1,150 and keeps an Overweight rating ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s websi Regeneron Pharmaceuticals, Inc. and Society ...